QINGDAO, CHINA, January 19, 2026 /EINPresswire.com/ — As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened ...
Amid shortages of cancer drugs in the U.S., the API Innovation Center will use continuous manufacturing technology and a partnership with Apertus Pharmaceuticals and the Glioblastoma Foundation to ...
Surveillance of the generic drug supply chain has typically focused on the number of manufacturers of finished drug products, but that approach may overlook vulnerabilities from having a limited ...
The US Food and Drug Administration (FDA)'s final guidance issued on Friday will help the generic drug industry prepare for completeness assessments for holders of Type II active pharmaceutical ...
Hosted on MSN
The Myth of All-American Drugs and What Trump’s Tariffs Miss About Pharma Supply Chains
It could be years before a cell therapy from Nkarta reaches autoimmune disease patients in the market, but CEO Paul Hastings still thinks about the impact of pharmaceutical tariffs here and now. With ...
“Although China’s share in India’s API imports has moderated marginally since 2010, dependence remains significant… It would take time to scale up domestic capacity,” stated a NITI Aayog report.
Indian companies filed 184 Type II DMFs with the US FDA in Q1 2026 against China's 149, reinforcing the country's leadership in API manufacturing and future generic drug development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results